Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brolucizumab vs PRP in proliferative diabetic retinopathy
NCT04278417Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2020
- Primary completion
- Oct 2023
- Modality
- scFv Fragments, Monoclonal Antibodies
- Countries
- 16
01
Overview
Phase 3, randomised, single-blind trial of brolucizumab in proliferative diabetic retinopathy (PDR) (2 arms), sponsored by Novartis. Primary endpoint: Change From Baseline in Best-Corrected Visual Acuity at 54 weeks. Started Nov 2020; status: completed.
02
Drugs
brolucizumab
03
Conditions
proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on NCT04278417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04278417.